Marketing-authorisation holder · United States
Maia Pharms Inc
4 medicines in 1 country, as authorisation holder.
Group structure
Part of
MAIAPharmaceutical groupOther companies in the group
Brazil1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Medicines
Every medicine in the registers under its name, current ones first.
4 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ANGIOMAX RTU250mg/50ml (5mg/ml) · Solution | Bivalirudin | United States | Marketed | 2019 |
| BORTEZOMIB2.5MG/ML (2.5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 3.5MG/1.4ML (2.5MG/ML) | 3.5MG/1.4ML (2.5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 3.5MG/3.5ML (1MG/ML) · Solution | Bortezomib | United States | Not marketed | 2022 |
| SINCALIDE0.005mg/vial · Powder | Sincalide | United States | Marketed | 2022 |
| SODIUM PHENYLACETATE AND SODIUM BENZOATE10%; 10% (2gm/20ml | 10%; 10% (5gm/50ml · Solution | Benzoato, Phenylacetate | United States | Marketed | 2016 |